Medistim ASA (STU:MD1) ROC %: 43.23% (As of Mar. 2026)


STU:MD1 Medistim ASA STU:MD1
96 GF Score
Price €20.10
GF Value €22.94
! 1 Warning Sign
View Full Analysis

What is Medistim ASA ROC %?

Medistim ASA STU:MD1 -0.99% 96 ROC % is 43.23% as of Mar. 2026. GuruFocus rates STU:MD1 with a GF Score™ of 96/100 and a GF Value™ of €22.94. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Medistim ASA's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 43.23%.

As of today (2026-06-27), Medistim ASA's WACC % is 4.83%. Medistim ASA's ROC % is 35.14% (calculated using TTM income statement data). Medistim ASA generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Medistim ASA  (STU:MD1) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Medistim ASA's WACC % is 4.83%. Medistim ASA's ROC % is 35.14% (calculated using TTM income statement data). Medistim ASA generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Medistim ASA ROC % Related Terms


Medistim ASA ROC % Historical Data

* Premium members only.

The historical data trend for Medistim ASA's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA ROC % Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.41 42.05 33.44 31.30 41.67

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.80 37.78 28.54 33.74 43.23
STU:MD1
96GF Score
Medistim ASA STU:MD1
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA ROC % Calculation

Medistim ASA's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=16.578 * ( 1 - 23.03% )/( (29.509 + 31.732)/ 2 )
=12.7600866/30.6205
=41.67 %

where

Medistim ASA's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=20.452 * ( 1 - 21.78% )/( (31.732 + 42.28)/ 2 )
=15.9975544/37.006
=43.23 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 43.23% mean?
Medistim ASA (STU:MD1) has a ROC % of 43.23% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's ROC % too high?
Medistim ASA's current ROC % is 43.23%. The Medical Devices & Instruments industry median ROC % is 1.26. Medistim ASA's value of 43.23% is 3331% above this industry median. Overall, Medistim ASA has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's ROC % compare to ABT and SYK?
Medistim ASA's ROC % of 43.23% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.26. Medistim ASA's value of 43.23% is 3331% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.26, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current ROC % of 43.23% is 3331% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current ROC % is 43.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current ROC % of 43.23%. The stock's GF Value™ is €22.94, compared to a current price of €20.10 — trading 12.4% below its estimated fair value. The current ROC % is 43.23% and 3331% above the Medical Devices & Instruments industry median of 1.26. Medistim ASA's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current ROC % is 43.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (STU:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €20.10 is trading 12.4% below its estimated GF Value™ of €22.94.

Key valuation signals for STU:MD1:

  • ROC %: 43.23%
  • GF Value™: €22.94 vs. price of €20.10 (12.4% below fair value)
  • GF Score™: 96/100 with 1 warning sign
  • Industry Position: 3331% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
96GF Score

Get the complete analysis for STU:MD1

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.10
Price
€22.94
GF Value